Podcasts about Packer

Riggs had to break up a FIGHT, is Adam a jerk for selling his Packer tix he got for FREE, Heading up north to Eagle River, and Alley is BACK at it!! Enjoy our Friday rewind,  Have a great weekend and GO PACK!! 💚💛💚💛 See omnystudio.com/listener for privacy information.

Special mid week podcast as its Packer week! First place in the NFC North is on the line. Raider week revisited, especially how tough Fields played, the dominance of Mack and Nagy's Club Dub. Updated injury report is included. Go Bears!

This game has the makings of the ultimate passing of the torch from Aaron Rodgers to Justin Fields of who has the keys to the throne of the NFC North for the next 10 years. At home, with momentum, could the Bears pull off the upset of the team that has been their kryptonite for decades? We tell you how the Bears can win this game and if they will.  Plus, who you got? Davante Adams vs. Allen Robinson, Damien Williams and Khalil Herbert vs. Aaron Jones and AJ Dillion and the Bears front four vs. the Packers O-line. It's Packer week! LETS GO!

Mike North, never shy of sharing provocative thoughts has plenty in this episode. There's a ton of laughs, too!

"Knowing God" - J. I. Packer

Chris and Dave discuss Mason Crosby doing his best to give fans across Wisconsin stress induced heart attacks. In a game that felt reminiscent of a 2012 special teams disaster, they still managed to pull it off in OT. Posting its first show in 2005, Packers Therapy is the longest-running Packers podcast on the Internet. Hosts Chris and Dave began the show as a way of capturing the spirited chats the two co-workers had about the team around the office. The two have no pretense about being experts: they are just two opinionated shareholders who love the team, follow it closely, but don't always see the Packers fortunes eye to eye. The guys encourage comments and questions via their Twitter feed @PackersTherapy or email to packerstherapy@yahoo.com and read and respond to as many as they can during each show. Packers Therapy is a part of the Packers Talk family of podcasts, serving up enough weekly podcasts to satisfy the most fervent of Packer fans. Follow Packers Talk on Twitter, Facebook, and subscribe over at iTunes.

"Knowing God" - J. I. Packer

"Knowing God" - J. I. Packer

Please join author Milton Packer and Associate Editor Justin Ezekowitz as they discuss the Perspective "Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the Journal and its editors. We're your co-hosts. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center. Dr. Greg Hundley: And I'm Dr. Greg Hundley, associate editor, director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam: Greg, it really is so great to be back with you chatting about the papers here in the Journal. Thank you for going solo and for just being the greatest partner on earth. Thank you for that. For everyone listening in, we are back with some gusto and especially with this feature discussion today. You are not going to want to miss it. We are talking to Dr. Milton Packer as well as Dr. Justin Ezekowitz. We are going to compare PARAGON and EMPEROR-Preserved trials in heart failure with preserved ejection fraction. A really interesting discussion you're not going to want to miss, but now let's start with some papers in today's issue. I'd like to start, please. Dr. Greg Hundley: You bet. Dr. Carolyn Lam: Greg, you know the optimal duration of antiplatelet therapy in patients with high bleeding risk with or without oral anticoagulation after coronary stenting? Well, that still remains a question. Today's paper is a pre-specified subgroup analysis of the MASTER DAPT trial and reports on the outcomes of patients with or without an oral anticoagulation indication in this study. Dr. Greg Hundley: Right, Carolyn. Remind us. What was the MASTER DAPT trial? What did it test? Dr. Carolyn Lam: Ah. MASTER DAPT investigated an abbreviated or one-month versus a non-abbreviated or three to 12-month dual antiplatelet therapy and a stopping of antiplatelet therapy at six months strategy after coronary stenting in an all-comer population at high bleeding risk. Dr. Greg Hundley: Carolyn, what did this subgroup analysis of outcomes in patients with and without oral anticoagulation show? Dr. Carolyn Lam: At 12 months of follow-up, ischemic and net risk did not differ with abbreviated versus non-abbreviated anti-platelet regimens in both subgroups, although significantly fewer clinically relevant bleeding events occurred in the group without an oral anticoagulation indication. Whereas only numerically fewer bleeding events occurred in the group with an oral anticoagulation indication that did not reach statistical significance. This subgroup analysis from the MASTER DAPT trial really adds additional evidence that dual antiplatelet therapy beyond one month in patients with or without an indication for oral anticoagulation really has no benefit and only increases bleeding risk. Dr. Greg Hundley: Oh, very important finding, Carolyn. Great research. Well, Carolyn, how the extracellular matrix microenvironment modulates the contractile phenotype of vascular smooth muscle cells and confers vascular homeostasis really remains elusive. Thus, these investigators led by Professor Wei Kong at Peking University applied protein-protein interaction network analysis to explore novel extracellular matrix proteins associated with the vascular smooth muscle cell phenotype. Dr. Carolyn Lam: Huh. Interesting. What did they find, Greg? Dr. Greg Hundley: Right, Carolyn. By combining an in-vitro and an in-vivo genetic mice vascular injury model, they identified nidogen-2, a basement membrane glycoprotein, as a key extracellular matrix protein for maintenance of vascular smooth muscle cell identity. Nidogen-2 exerted its protective function via direct interaction and modulation of Jagged1-Notch3 signaling. Dr. Carolyn Lam: Wow! Nidogen-2 and Jagged1-Notch3. I always learn so much. What are the clinical implications, Greg? Dr. Greg Hundley: Right, Carolyn. Perhaps targeting nidogen-2 to precisely modulate Jagged1-Notch3 signaling, well, that may provide novel therapeutic strategy for atherosclerosis and post-injury restenosis. Dr. Carolyn Lam: Very nice. Well, in the next paper, we discuss inflammation in heart failure. We know that inflammation contributes to the pathogenesis of heart failure, but there is limited understanding of inflammation's potential benefits. Interesting, huh? Well, these authors, Dr. Wollert and colleagues from Hannover Medical School in Germany, identified an adaptive crosstalk between inflammatory cells and cardiomyocytes that protects against persistent afterload stress-induced heart failure in mice. Monocytes and macrophages produced myeloid-derived growth factor in the pressure overloaded myocardium to augment SERCA2a expression in cardiomyocyte's calcium cycling and contractility. Myeloid-derived growth factor plasma concentrations were also found to be elevated in patients with aortic stenosis and to decline after aortic valve implantation indicating that pressure overload also triggers myeloid-derived growth factor release in humans. Dr. Greg Hundley: Carolyn, really informative preclinical science, but what are the clinical implications? Dr. Carolyn Lam: Ah. These observations molecularly defined a feature of the inflammatory response to hemodynamic overload that protects against heart failure development. Inflammation's beneficial trade therefore need to be considered when developing inflammation as a therapeutic target in heart failure. All of this is really discussed in a lovely editorial entitled Inflammation and Heart Failure: Friend or Foe? That's by Drs. Hajjar and Leopold. Dr. Greg Hundley: Great job, Carolyn. Well, my next paper focuses on resistant hypertension. Carolyn, although lifestyle modifications generally are effective in lowering blood pressure among patients with unmedicated hypertension or those treated with one to two antihypertensive agents, the value of exercise and diet for lowering blood pressure in patients with resistant hypertension is unknown. To address this, Professor James Blumenthal and co-authors at Duke University Medical Center enrolled 140 patients with resistant hypertension with an average age of 63 years, 48% women, 59% black, 31% diabetes, and 21% with chronic kidney disease and randomly assigned them to A, a four-month cardiac rehab center-based program of lifestyle modification. We're going to call that C-LIFE, consisting of dietary counseling, behavior and weight management, and exercise. Or number 2 or the B, a single counseling session providing standardized education and physician advice. We'll call that SEPA. Dr. Greg Hundley: The primary endpoint was clinic measured systolic blood pressure. Secondary endpoints included 24-hour ambulatory blood pressure and selective cardiovascular disease biomarkers including baroreflex sensitivity to quantify the influence of baroreflex on heart rate; high-frequency heart rate variability to assess vagally-mediated modulation of heart rate; flow-mediated dilation to evaluate endothelial function; and pulse wave velocity to assess arterial stiffness; and then finally left ventricular mass to characterize left ventricular structure and remodeling. Dr. Carolyn Lam: Wow! That is a very, first of all, important clinical question. Then also, just very intricate methodology in assessing this. What did they find? Dr. Greg Hundley: Right, Carolyn. Between-group comparisons revealed that the reduction in clinic systolic blood pressure was greater in C-LIFE compared with SEPA. Next, 24-hour ambulatory systolic blood pressure also was reduced in C-LIFE with no change in SEPA. Then next, compared with SEPA, C-LIFE resulted in greater improvements in baroreflex sensitivity, high-frequency heart rate variability, and flow-mediated dilation. There was no between-group differences in pulse wave velocity or LV mass. Dr. Greg Hundley: Carolyn, diet and exercise can lower blood pressure in patients with resistant hypertension. When delivered in a cardiac rehabilitation setting, a four-month program of diet and exercise as adjunctive therapy, results in a significant reduction in clinic and ambulatory blood pressure, and improvement in selected cardiovascular disease biomarkers. Dr. Carolyn Lam: Wow! Really nice, Greg. Okay. Well, looks like we're all going to round up already with what else there is in today's issue. Let me start. There's an exchange of letters between Drs. Fang and Vinceti regarding the article Blood Pressure Effects on Sodium Reduction: Dose-Response Meta-analysis of Experimental Studies. Dr. Greg Hundley: Right, Carolyn. I've got a few things in the mail bag. First, Professor Anker has a Research Letter regarding the Kidney Function After Initiation and Discontinuation of Empagliflozin in Heart Failure Patients With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Dr. Gerstenfeld has an ECG challenge entitled Atrioventricular Block with Narrow and Wide QRS: The Pause That Refreshes. Then lastly, Dr. Donald Lloyd-Jones has an AHA update regarding the American Heart Association's focus on primordial prevention. Well, Carolyn, I can't wait to hear this fantastic feature discussion with you and Dr. Packer. How about we jump to that? Dr. Carolyn Lam: Great. Let's go, Greg. Dr. Carolyn Lam: Because side-by-side exam of PARAGON and EMPEROR is like side-by-side of... Dr. Justin Ezekowitz: You can compare our new and our old prime minister much like your paper did. Dr. Milton Packer: Yeah, yeah. Dr. Justin Ezekowitz: There are [crosstalk] and it could be viewed until they perform in the broader world how it goes. You don't quite know. Dr. Milton Packer: The only problem is you can't do a head-to-head comparison of the old prime minister and the new prime minister. Dr. Justin Ezekowitz: That is true except that the head-to-head comparison includes excellent care by both the new and the old. I think that comparison's going to be pretty equal. I think we can case-control that one. Dr. Carolyn Lam: I really liked that that was politically correct because we are recording. Everybody, welcome to the feature discussion. I am here with Dr. Milton Packer from Baylor and he really needs no introduction. We're discussing heart failure with preserved ejection fraction. As well as our associate editor, Dr. Justin Ezekowitz from University of Alberta. Hence, in case anybody's wondering, we were talking about the Canadian elections. Let's just launch straight into it, a side-by-side comparison of PARAGON and EMPEROR-Preserved. Dr. Packer... Milton, if I may, what in the world drove you to do this? Dr. Milton Packer: My God. Oh, my God. Yes. Dr. Carolyn Lam: Tell us about what drove you to do this and please, if you could just summarize the results. Dr. Milton Packer: Well, let me just say from the outset that this was a commentary, not an original research article. Dr. Carolyn Lam: Yes. Dr. Milton Packer: The commentary was motivated by two very straightforward observations. We had two large scale outcome trials of two different drugs in heart failure with a preserved ejection fraction. I was privileged to serve as you were, Carolyn, on the leadership committees of both trials. It's not as if we have involvement in only one trial. We have involvement in both trials and we are very proud of that involvement. Dr. Milton Packer: One trial came in with a effect size of about 13% on its primary endpoint with a borderline P-value. A second trial, EMPEROR-Preserved, came in with a 21% reduction and its primary endpoint with a really small and persuasive P-value. The two patient populations in the two trials were really amazingly similar. We wanted to understand why it was 21% in one trial and persuasively so and why it appeared to be smaller in the PARAGON trial with sacubitril/valsartan. We thought, well, maybe that difference was related to how endpoints were defined or maybe that difference was related to the influence of ejection fraction. The reason we got excited about that was that as almost everyone knows, PARAGON found an influence of ejection fraction on the effect of sacubitril/valsartan in patients with HFpEF. We found an influence of ejection fraction on the effect of empagliflozin in HFpEF in EMPEROR-Preserved. We wanted to understand whether that influence was similar in the two trials. Dr. Milton Packer: Just to make life simple, PARAGON had created certain cut points for ejection fraction. They had presented and previously published in Circulation endpoints based on those cut points of ejection fraction. All we did was we used their endpoints and their cut points, and we put the two trials side by side. We did not do a statistical comparison of the effect size. There're actually no P-values in the whole commentary. But what we wanted to see was: Was the shape of the ejection fraction influence relationship similar or different in the two trials? Well, very simple. In PARAGON, as has been reported, there was a linear relationship: as ejection fraction increased, the effect of sacubitril/valsartan got smaller. In EMPEROR-Preserved, there was also an attenuation at a highest ejection fraction, but the relationship wasn't linear. It was like a hockey stick. It was flat and then went up at an ejection fraction over 62.5, which was the cut point that PARAGON used. Dr. Milton Packer: When we compared patients between the low 40s and the low 60s, the effect size in empagliflozin appeared to be larger than the effect size of sacubitril/valsartan in that ejection fraction group using the same endpoints. In fact, for hospitalizations for heart failure, which is really what SGLT2 inhibitors do, it was twice as great with empagliflozin in EMPEROR-Preserved than with sacubitril/valsartan in PARAGON-HF. We thought this was really interesting. We put the pictures up side by side. We wrote a commentary and Circulation was so kind to accept it. Dr. Carolyn Lam: Oh, but Milton, you were very, honestly as always, very clever to have done this analysis. But if I could reiterate a few things for the audience, which is very important. First of all, as you rightly first pointed out, it's a perspective piece. It is not a head-on comparison with P-values. It could not be. Let's just also give the audience a bit of background in that PARAGON included patients with an ejection fraction of 45% and above. EMPEROR-Preserved was above 40. PARAGON looked at total heart failure hospitalizations and cardiovascular death as a primary outcome. EMPEROR looked at first cardiovascular death or heart failure hospitalization. Dr. Carolyn Lam: Let's just remember the designs were different. Of course in the comparison, PARAGON compared sacubitril/valsartan versus valsartan. I like the way you very carefully wrote in your study that it was more a study of neprilysin inhibition since it's sacubitril/valsartan against valsartan and it was empagliflozin versus placebo. We know that it's important to state that as a basis. Then really important to say to everybody out there, pick up our journal. You must look at this bigger. I myself have already cited it at least twice already, Milton, because people will just naturally ask that. "Are the results different because of ejection fraction or different endpoints?" What you did there in that beautiful figure is that you tried as best as you can to match it up in terms of ejection fraction bins and match it up in terms of hospitalizations. There. I just wanted to state those few things, but I'm really- Dr. Milton Packer: Oh, no. No. Carolyn, you're 100% right. That's why there are couple of things. I just want to underscore what you said because I think your points were spot on. First of all, we really lined up the endpoints and the ejection fraction. We tried our best to compare apples and apples. It would not have been a useful exercise for us to compare different endpoints and different ejection fraction subgroups. But I just want to make sure that everyone understands: I'm a big fan of sacubitril/valsartan and I'm a big fan of neprilysin inhibition. As you know, both PARADIGM-HF and PARAGON-HF weren't really tests of sacubitril/valsartan; they were tests of neprilysin inhibition. They were great tests at that. PARAGON in particular was a great test of that. We're comparing neprilysin inhibition and SGLT2 inhibition. Dr. Milton Packer: But here's my most important point: we do not want people to choose one over the other. That was not the intent. We think that there are data in patients with certain ejection fractions, let's say between 40 and 60, I'm just creating a range, where both interventions are appropriate. Now I understand there are cost considerations and I don't want to minimize that, but we are not suggesting that anyone prefer one drug over the other. All we wanted to do was we wanted to ask the question: Since the effect size in one trial seemed to be different than the effect size in the other trial, what were the ejection fraction subgroups that represented that difference? We found that the patients with ejection fractions greater than 60, 65% did not contribute to that difference. It was the patients with lower ejection fractions that contributed to the difference. I hope that's helpful. Dr. Carolyn Lam: Ah. That's wonderful. Justin, have you recovered from the talk about the Canadian elections? Dr. Justin Ezekowitz: Oh. I have indeed. Dr. Carolyn Lam: I'm on swinging. Dr. Justin Ezekowitz: I have indeed. Thanks for recognizing that Canada just had a major election we carried out in six weeks. But, Milton, I really enjoyed reading this. Maybe I can just ask you about two elements within this perspective piece, which is number 1, what's incredibly concordant is a lack of difference across cardiovascular death for both agents in both trials regardless of the trial differences and the potential differences in patient populations recruited; that's number 1. It's incredibly flat for cardiovascular death. Dr. Justin Ezekowitz: But number 2 is there is a danger in comparing trials even non-statistically. That's often a pitfall we get into, but we have to put some frame of reference on that. What is the one or two key things you think differ between PARAGON and EMPEROR-Preserved that you say, "You really need to look at these trials differently"? Those two questions came to mind when looking at this great figure that you produced. Dr. Milton Packer: Okay. The first question is so much easier and that is that these drugs don't reduce cardiovascular deaths. Full stop. It's really interesting because sacubitril/valsartan reduces cardiovascular death in people with ejection fractions of 40% or less, but not in patients with ejection fraction greater than that. The primary effect is heart failure hospitalizations. Empagliflozin didn't reduce cardiovascular death even in patients with the ejection fraction less than 40% or greater than 40%. What we're really, really talking about two drugs where the major effect is a reduction in heart failure hospitalizations. That comes out whether you do the analysis as time-to-first-event or total heart failure hospitalizations. Dr. Milton Packer: Of course, we're looking forward to the DELIVER trial with dapagliflozin. My own personal expectation is they're going to come out with a very striking effect on heart failure hospitalizations and not on cardiovascular deaths. Cardiovascular deaths in patients with HFpEF is really... It's a hard goal because only half of the deaths are cardiovascular. These patients have so many comorbidities that influence prognosis. The other thing, which is really important, is that heart failure hospitalizations only represented 18% of all hospitalizations in these patients; it's really small. I think of empagliflozin as being a treatment of the heart failure of HFpEF, not a treatment for HFpEF. I hope that makes sense. Justin, what was your second question? Dr. Justin Ezekowitz: Absolutely. Dr. Milton Packer: Oh, the differences between- Dr. Justin Ezekowitz: Yeah. Thank you, Milton. Dr. Milton Packer: Okay. There's always differences between two trials. As I said before, Carol and I were involved in both trials. They were done slightly at different times. They didn't overlap. Remember that the cut points in the two trials, one was 40%, one was 45%, really didn't matter to our analysis because we corrected for that in our ejection fraction subgroups. I was actually really much more impressed by the similarities than by the differences, but here's the catch. HFpEF is an incredibly heterogeneous disease. When we look at baseline characteristics, we're looking at means, medians, percentages. We're not picking up on any heterogeneity and there's a lot of heterogeneity. I actually think that HFrEF is a reasonably homogeneous disease. I think HFpEF is an incredibly diverse disease with a whole host of different disorders. What I'm amazed by is that we actually got an effect size that was greater than 20% in an all-comers HFpEF analysis. Dr. Milton Packer: But in all honesty, Justin, it wasn't really all-comers. We excluded people with BMIs over 45. There are a lot of patients who are obese and had BMIs greater than 45 who have HFpEF. By the way, especially in Texas. I didn't say that. We didn't enroll those patients. In all honesty, if I had to do it all over again, I would have. By the way, PARAGON didn't enroll them either. Dr. Carolyn Lam: Well, this is an incredible conversation. I know that we could just do a whole hour of chatting about what this implies for the higher ejection fraction, what this implies for how we should be treating heart failure. I don't even dare to ask for some last words maybe from both Justin and Milton, but recognizing that the time is short, anything else to add? Dr. Milton Packer: I think Justin should do last words. Dr. Justin Ezekowitz: Well, let me summarize by saying there is a hockey stick. We love hockey sticks in Canada. A simple and an excellent comparison. I think people should really look at that figure to understand it, but do not undertreat your patients with HFpEF and look at these with a grain of salt. Thanks for joining us, Milton. Thanks, Carolyn. Dr. Milton Packer: Thank you so much. Dr. Carolyn Lam: On behalf of Greg and I, you've been listening to Circulation on the Run. Thank you so much for joining us today and don't forget to tune in again next week. Dr. Greg Hundley: This program is copyright of the American Heart Association 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors, or of the American Heart Association. For more, visit ahajournals.org.

Chris Lempesis is back - and on his birthday! - to break down Green Bay's completely insane 25-22 overtime road win over the Cincinnati Bengals on Sunday at Paul Brown Stadium. He takes you through his emotions from the final two-plus minutes of regulation through overtime. He talks about Mason Crosby's rough day, one that ultimately ended in redemption. He praises several members of the offense and defense, but also describes how each unit still has work to do. Lastly, he takes questions and comments received from listeners via Twitter, email and Facebook. You can follow Chris on twitter at LempsMKE (@ItsJustChrisNow) LempsTalkingPack is a part of the Packers Talk family of podcasts, serving up enough weekly podcasts to satisfy the most fervent of Packer fans. Follow Packers Talk on Twitter, Facebook, and subscribe over at iTunes

Mason Crosby panics Packer fans... pulls through in OT for win over Bengals | Chargers/Browns score 40+ points in the fourth quarter ALONE! | Cowboys beat Giants, who lose Daniel Jones and Saquon Barkley to injury. See omnystudio.com/listener for privacy information.

"Knowing God" - J. I. Packer

It's always fun when Cole joins the zoom! -Part-Owner of the Green Bay Packers, Cole, join Josh & Kyler to give instant reaction to TNF -The boys then preview the NFL and CFB Weekend Slate, giving some great betting advice! -Stick around until the end to hear the locks of the week from us 3 and.... THE BYB PARLAY IS BACK & WON"T MISS THIS TIME! (Probably) All this + A LOT more fun, follow us on all social media platforms to share the content with your friends! Thanks for listening! Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Wendy's Big Show, Hour 3:The Bengals are 3-1 and are at the top of one of the best divisions in football. But, several Packer fans are just expecting the Packers to run away with this one. Do you think Packer fans are underestimating Cincy? LeRoy, Gary, and Sparky warn against it. Then, Grant McAuley from ForTheDiamond.com joins the show to give us the Braves' perspective against the Brewers in the NLDS. See omnystudio.com/listener for privacy information.

Host Reed Galen is joined by Dominic Packer and Jay Van Bavel, Professors of Psychology and Co-Authors of the new book, The Power of Us: Harnessing Our Shared Identities to Improve Performance, Increase Cooperation, and Promote Social Harmony. They discuss how the definition of identity fits into today's society, how identity has shifted as political polarization has increased, and the effect the COVID-19 pandemic has had on the identities of both individuals and groups. Be sure to pick up The Power of Us at your favorite book retailer.

In this episode of Tip of the Iceberg Podcast Amy Sowder Retail Editor of Produce Market Guide and Tom Karst Editor and Chief of The Packer speak with Wendy Reinhardt Kapsak, MS, RDN, President and CEO of Produce for a Better Health, regarding shifting the focus beyond produce sales to consumption. She also discusses PBH's Have a Plant Nation and its Ambassadors. Visit The Packer to learn more.  See omnystudio.com/listener for privacy information.

The Green Bay Packers play a really tough oppenet this week in the Cincinnati Bengals, what are the Bengals strengths on offense and how will the Bengals try to attack the Packers, how can the Packers exploit this Cincinnati team and counter the Bengals offensive efforts. What should Packer fans expect from free agent signing Jaylon Smith, and how should the Packers use him. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/beerdeerandcheese/support

The Green Bay Packers not only get a big win at home against the Steelers, but take two trips down memory lane with Randall Cobb doing a Lambeau Leap, and then a welcome to the original Lambeau Leaper, LeRoy Butler, and the rest of the 1996 Super Bowl Championship Team making a return visit at halftime. But, despite all that nostalgia, a critical injury on defense leaves the team even more short-handed as they travel to take on the Bengals on Sunday. It's four quarters of Packers football with CD, Jersey Al, and Kelly on Cheesehead Radio! First Quarter:  The Packers get a big win against the Steelers at home Second Quarter: But take a big loss with Jaire Alexander out of the lineup Third Quarter: The 1996 Super Bowl team returns to celebrate 25 years Fourth Quarter:  And Aaron Rodgers and Mike Tomlin make the meme of the year Overtime: Packers/Bengals Game Predictions Cheesehead Radio is a part of the Packers Talk family of podcasts, serving up enough weekly podcasts to satisfy the most fervent of Packer fans. Follow Packers Talk on Twitter, Facebook, and subscribe over at iTunes.

"Knowing God" - J. I. Packer

Chris and Dave discuss yet another Packers win, as week 1 begins to feel like a bad dream, and hope is starting to be restored in the minds of cheeseheads across the globe. Many things to like about what happened on Sunday afternoon, and although the defense is looking much better, will some disturbing injuries change the fate of the Packers in upcoming weeks? Speaking of disturbing, the makings of a conspiracy the likes of Watergate begins to unfold regarding the betting lines. Posting its first show in 2005, Packers Therapy is the longest-running Packers podcast on the Internet. Hosts Chris and Dave began the show as a way of capturing the spirited chats the two co-workers had about the team around the office. The two have no pretense about being experts: they are just two opinionated shareholders who love the team, follow it closely, but don't always see the Packers fortunes eye to eye. The guys encourage comments and questions via their Twitter feed @PackersTherapy or email to packerstherapy@yahoo.com. Packers Therapy is a part of the Packers Talk family of podcasts, serving up enough weekly podcasts to satisfy the most fervent of Packer fans. Follow Packers Talk on Twitter, Facebook, and subscribe over at iTunes.

"Knowing God" - J. I. Packer

"Knowing God" - J. I. Packer

Chris Lempesis is back to break down Green Bay's 27-17 win over the Pittsburgh Steelers on Sunday at Lambeau Field. He is once again over the moon about the performance of the new-look offensive line. He's also thrilled about the showings from Aaron Jones, AJ Dillon and Randall Cobb and he tells you what the formula is for the Packers to reach their peak, offensively. He's obviously much less excited about the injury suffered by Jaire Alexander and he tells you what that could mean for the defense going forward. Other topics discussed include the fall of Ben Roethlisberger, the rise of Corey Bojorquez and the '96 Super Bowl team. Lastly, he takes questions and comments submitted from listeners via Twitter and email. You can follow Chris on twitter at LempsMKE (@ItsJustChrisNow) LempsTalkingPack is a part of the Packers Talk family of podcasts, serving up enough weekly podcasts to satisfy the most fervent of Packer fans. Follow Packers Talk on Twitter, Facebook, and subscribe over at iTunes

"Knowing God" - J. I. Packer

Paul, Michael, and Geoffrey discuss Aaron Rodgers drama, the future of Jordan Love, the availability of TJ Watt, and if he'll push to play at Lambeau, the vulnerabilities of the Packer defense, Aaron Jones, Davante Adams, and who else matters on the Packer offense. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome to Dead Men Walking Podcast Book Suggestions. Released on the first and third Friday of each month, Greg & Jason each pick a book they have read and discuss and review it. They each give a quick synopsis of the book they chose, why they liked it, and who would be the best audience for it.  This week Jason chose : "Psalms for Trials" by Lindsey Tollefson and Greg discussed "Evangelism and the Sovereignty of God" by J. I. Packer. Enjoy!Support the show (https://cash.app/$dmwpodcast)

The Cheesehead Radio Gang break down the Green Bay Packers thrilling 30-28 win over the San Francisco 49ers with four quarters of great Packers Talk. Listen in as Jersey Al, CD, and Kelly break down Aaron, the refs, and Allan Lazard, and a whole lot more! 1st Quarter: The Packers hit on all cylinders with Mason Crosby being clutch 2nd Quarter: Yosh Nijman...wait, who?...locks down Nick Bosa 3rd Quarter: The officiating was....sus 4th Quarter: And a special teams breakdown has a silver lining Overtime: Packers/Steelers Game Predictions Cheesehead Radio is a part of the Packers Talk family of podcasts, serving up enough weekly podcasts to satisfy the most fervent of Packer fans. Follow Packers Talk on Twitter, Facebook, and subscribe over at iTunes.

CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 6 Dr. Packer reflects on a conversation he had with Dr. Eugene Braunwald about mentorship and its role in immortality. This episode is particularly meaningful to the CardioNerds team as mentorship and sponsorship is such an important part of the CardioNerds mission. Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.

"Knowing God" - J. I. Packer

Chris and Dave discuss an epic victory against the 49ers in California. Despite being sick with... something... Dave has a lot to say about a game that was a nail biter in the last quarter. Are the Packers back? Or is cautious optimism, a staple of Packers therapy, the best mentality moving into next week's game against the Steelers. Posting its first show in 2005, Packers Therapy is the longest-running Packers podcast on the Internet. Hosts Chris and Dave began the show as a way of capturing the spirited chats the two co-workers had about the team around the office. The two have no pretense about being experts: they are just two opinionated shareholders who love the team, follow it closely, but don't always see the Packers fortunes eye to eye. The guys encourage comments and questions via their Twitter feed @PackersTherapy or email to packerstherapy@yahoo.com and read and respond to as many as they can during each show. Packers Therapy is a part of the Packers Talk family of podcasts, serving up enough weekly podcasts to satisfy the most fervent of Packer fans. Follow Packers Talk on Twitter, Facebook, and subscribe over at iTunes.

"Knowing God" - J. I. Packer

Josh Darrow talks ACC and Miami football with ACC Network play-by-play announcer and "Packer & Durham" co-host Wes Durham, who discusses the state of the conference, which teams have the best chance of making it to Charlotte and how college football continues to evolve on and off the field.

"Knowing God" - J. I. Packer

The Wendy's Big Show, Hour 4: Green Bay is now 2-1 after beating the San Francisco 49ers on the road. With a bunch of questions marks from the offseason that crept into the regular season, which Packer player do you think redeemed themselves the most on Sunday? LeRoy, Gary, and Sparky discuss.  See omnystudio.com/listener for privacy information.

CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 5, Dr. Packer shares his thoughts on the term “guideline directed medical therapy,” guidelines in general, and the challenges of using the ejection fraction to measure systolic function. Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.

Chris Lempesis is back to break down Green Bay's thrilling 30-28 road victory over the San Francisco 49ers on Sunday night at Levi's Stadium. He describes how he was feeling as the Packers fell behind late, then rallied in the final 37 seconds to pull out the win. He, of course, showers praise on Aaron Rodgers, Davante Adams and Mason Crosby. He also talks about the stellar play of the offensive and defensive lines, among others. And yes, he talks at length about the horrendous officiating. Lastly, he takes questions and comments received from listeners via Twitter and emai You can follow Chris on twitter at LempsMKE (@ItsJustChrisNow) LempsTalkingPack is a part of the Packers Talk family of podcasts, serving up enough weekly podcasts to satisfy the most fervent of Packer fans. Follow Packers Talk on Twitter, Facebook, and subscribe over at iTunes l.

Today is a "Question of the Month" episode where we share something we recommended and WHY. We look at the strategy of dripping content to keep people wanting to know what happens next ( the Zeigarnik effect ). Sponsor: Novel Marketing Podcast A lot of podcasters plan to write a book but they don't know where to start. Our sponsor the Novel Marketing Podcast is here to help. Thomas Umstattd Jr is a wealth of knowledge and he can get you going in the right direction. Check out https://www.schoolofpodcasting.com/author Participants Matt from The Author Inside You Scott from What Was That Like? Jennifer Bourbon Barrel Podcasting Timothy from Podwrecked and Create Art Podcast Haley from Adoptees On Jerry from Beyond the Rut Mark from the History of North America Wayne from the Packer's Fan Podcast, and Media Voice Overs. Fred from Grump Old Bears MENTIONED IN THIS PODCAST Podcast Rodeo Show Dumb People With Terrible Ideas Social Media Marketing Podcast Project Hail Mary Samson Q2u Podtrak P4 Dave's "My Gear" page. Leading the Bleeding Podcast Podcasting 2.0 New Podcast Apps No Agenda Stream The Chosen Virgin River Libsyn promo code sopfree to get a full month free. Ready To Start Your Podcast You may think nobody would listen to you, but I'm here to tell you they will. I have proven strategies to help you identify exactly what your audience wants. You will sound professional, and won't have to spend a million dollars to sound great. Learn through our online tutorials, live group coaching and a private Facebook Group filled with brilliant podcasters. Join worry-free with a 40-day money-back guarantee. See schoolofpodcasting.com/start TOPICS 01:34  Autographed Copies of Profit From Your Podcat 02:10  The Show I Love to Hate 03:21  Zeigarnik effect 05:01  What Makes a Good Podcast? 06:39  What Happens Next? 07:48  Example of Dripping Content 09:11  Sponsor: Novel Marketing Marketing Podcast 13:19  Scott Johnson 15:54  Jennifer Longworth 17:15  Matt Rafferty 18:21  Timothy Kimo Brien 20:39  Haley Radke 23:09  Jerry Dugen 24:56  Mark Vinet 26:02  Wayne Henderson 27:13  Fred Castenada 28:35  Dave Jackson 33:10  October Question of the Month 38:20  Quick Wrap Up 39:08  Mastering Your Craft is a Goal 39:44  Libsyn Promo Code sopfree 40:38  Coming Soon Follow the Show and Never Miss an Episode on: Apple - Google - Spotify - Amazon Check out New Podcast Apps for apps to stream bitcoin to podcasters. Did You Get Value From This Episode? Enjoy the Show? Buy Dave a Coffee and give some of that value back. 

CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 4, Dr. Packer shares his perspective on the revolutionary SGLT2 inhibors. We discuss the mechanisms of action and the data regarding their role in the care of heart failure patients. This episode is particularly historic in that Dr. Packer shares his thoughts about the EMPEROR-PRESERVED trial well before the data was available. Also see Dr. Mark Belkin's DocWire News article EMPEROR's New Groove? Empagliflozin Provides Long-Awaited Treatment for HFpEF where Dr. Packer is quoted as saying “we are pleased to have the first trial in patients with HFpEF that shows an unequivocally positive and clinically important result. We are looking forward to many secondary papers that will provide detailed information about what we have found, and what it means for patients.” Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.

"Knowing God" - J. I. Packer

Madison Packer | Average to Savage EP142 by Paul Guarino

The Packers defeat the Lions in what appears to be a blowout game on paper, but Chris and Dave peel back the onion to find a rotten center. Plenty of things to be worried about despite the victory, as we collectively clench our teeth for another prime time game this Sunday against a much more formidable foe. Chris's audio equipment is more optimistic, proof being it's attempt to sabotage the truth of what happened Monday night by cutting in and out.Patreon:  Posting its first show in 2005, Packers Therapy is the longest-running Packers podcast on the Internet. Hosts Chris and Dave began the show as a way of capturing the spirited chats the two co-workers had about the team around the office. The two have no pretense about being experts: they are just two opinionated shareholders who love the team, follow it closely, but don't always see the Packers fortunes eye to eye. The guys encourage comments and questions via their Twitter feed @PackersTherapy or email to packerstherapy@yahoo.com and read and respond to as many as they can during each show. Packers Therapy is a part of the Packers Talk family of podcasts, serving up enough weekly podcasts to satisfy the most fervent of Packer fans. https://www.patreon.com/packerstherapy PayPal: Packerstherapy@yahoo.com

The Green Bay Packers reverse their fortunes in Week 2, taking the division rival Detroit Lions behind the proverbial woodshed for a 35-17 victory that almost....ALMOST....made us forget the nightmare in Week 1. Nothing was more inspiring than running back Aaron Jones, who four touchdowns and bittersweet dedication to his father won over the hearts of Packer fans everywhere. But the Packers turn around to head to San Francisco, where they take on the 2-0 49ers on their home turf as a 3.5-point underdog. A quality opponent will be a great measuring stick to see if the Packers we saw against the Saints or the Lions are the ones we can expect from here on out. Join CD, Al, and Kelly as we break it down for a great Packers conversation. 1st Quarter: The Packers turn it around against the Lions, but are we happy? 2nd Quarter: Aaron Jones conquers the endzone and the hearts of Packers fans 3rd Quarter: The Jace Sternberger experiment comes to an unceremonious end 4th Quarter: The Packers face a formidable quality opponent on Sunday Night Overtime: Packers/49ersGame PredictionsCheesehead Radio is a part of the Packers Talk family of podcasts, serving up enough weekly podcasts to satisfy the most fervent of Packer fans. Follow Packers Talk on Twitter, Facebook, and subscribe over at iTunes.

Does Monday night's victory change your perception of the Packers? l Sterling Shepard, New York Giants wide receiver l Ben Simmons won't report to Sixers training camp See omnystudio.com/listener for privacy information.

The Packers took care of the Lions, pulling away in the second half to win 35-17.  We start with the positives, breaking down the offensive side of the ball and the big game from Aaron Jones, Davonte Adams, Robert Tonyan, and Aaron Rodgers (00:01:35).  On the defensive side of the ball, we discuss whether absent an injury, Kevin King has started his last game as a Packer (00:28:20), and our impressions of the continued expanded role of rookie Eric Stokes at cornerback. Lastly, we look at what answers for how we can get an improvement in the play of the defensive line and pass rush (00:34:50). https://lombardislegends.com Twitter: @LombardiLegends   Instagram: LombardisLegends Facebook: @LombardisLegends YouTube Channel: https://www.youtube.com/channel/UCAdWjeSi1MY347si-6RucUg Intro/Outro Music – Green And The Gold (West Coast Packers Anthem) (feat. Joey G).  Played with permission from Young Trav and Joey G - Support them (@youngtrav_951 and @jhussle714 on IG): https://music.apple.com/us/artist/young-trav/259914092

We have a great show for you today! 9-4 again last week in College Football bring us to 27-14 up 31 Units for the season.  NFL finished 6-6.  First, Kiev O'Neil recaps College Football Week 3 and NFL week 2 with some upsets and some great performances.   What should we look for when handicapping college football week 4?  Then, he gets into some misleading final scores in both sports and some motivational spots for College Football week 4 and NFL week 3.   Next, Kiev gives out a big College Football FREE PLAY for week 4!  Then, D-Nasty is at the Packer game so Kiev goes solo to break down Fantasy Football week 3.  Who was injured this week?  Waiver wire analysis.  Non-starters trending up and players that could bust.  Finally, Kiev give's out his nasty sleeper of the week that could help you win your matchup or DFS!  Should you have any questions for us or would like us to break down a game, please feel free to tweet us @TheOddsBreakers Should you need a sportsbook please visit MyBookie.ag and use the promo code, “TheOddsbreakers” to get a 100% sign up bonus!!!! Terms, conditions and location apply. #Sportsbetting #FreePicks #FreePlays #Gamblingtwitter #NCAA #NBA #NHL #NFL #UFC #Horseracing If you want to subscribe to and get some very frequent winners Click Here, please become a member of The OddsBreakers by clicking shop and gain access to premium picks BEFORE the line moves!  Please visit theoddsbreakers.com and click shop and pick one of our great handicappers including Kiev O'Neil @OBKiev.  We are giving away a FREE THE ODDSBREAKERS T-shirt with all signups.   You could also support us at Patreon.com for only $10 a month and get some benefits and merchandise.

CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 3 Dr. Packer reflects on the value of neutral trials and recounts the journey that led to the PARADIGM Trial Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.

CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 2 Dr. Packer shares his journey as the trailing spouse and tells the story of how the neurohormonal hypothesis was developed. Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.

On this episode of Help Me Teach the Bible, Nancy Guthrie talks with Dick Lucas in London's Proclamation Trust offices about what makes an excellent Bible teacher. We talked about how a teacher studies and prepares to teach, dealing with discouragement as a teacher, as well as the temptation to pride.Lucas was rector of St. Helen's Bishopsgate from 1961 to 1998. In 1986, he founded the Proclamation Trust to train men and women to correctly handle Scripture through prayerful study of the text in light of its context in both the biblical book and the Bible as a whole. Now in his early 90s, Lucas was a key figure along with John Stott and J. I. Packer in shaping the conservative evangelical movement in the UK during the 20th century. He still has an active and influential ministry, preaching and speaking at conferences and serving on the leadership team of the Cornhill Training Course.You can hear Lucas's own Bible teaching through these audio resources:The message of Galatians, Lucas's most recent teaching to the staff at St. Helens BishopsgateDick Lucas Sermon Archive

(0:00) intro(0:35) Steelers vs Bills (15:10) Eagles vs Falcons(34:50) Panthers vs Jets (36:50) Vikings vs Bengals(51:10) Lions vs 49ers (55:50) Texans vs Jags(1:12:50) Chargers vs WFT(1:25:50) Chiefs vs Browns (1:33:50) Pats vs Dolphins(1:42:50) Saints vs Packer(1:52:20) Broncos vs Giants(1:57:20) Bears vs Rams